Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer

NCT06727773 is registered in ClinicalTrials.gov with UNC Lineberger Comprehensive Cancer Center as lead sponsor.

NCT NCT06727773
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06727773 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Memantine and Exercise to Improve Cognitive Function and Modulate Biological Pathways of Cognitive Decline During Chemotherapy in Breast Cancer
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
August 19, 2025
Completion date
June 15, 2029
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, breast cancer stage i, breast cancer stage ii, breast cancer stage iii, cognitive change, cognitive decline, cognitive impairment, locally advanced breast cancer